Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Paricalcitol Improves Anemia of Inflammation
NCT02876211 · Hospital Son Espases · PHASE4 · terminated · last registry update 2024-12-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficult inclusion of patients diagnosed with renal anemia in chronic hemodialysis patients without hyperparathyroidism.” | – | Registry record, Hospital Son Espases |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VDR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-19Also stopped (terminated): Anhui Medical University, a drug against VDR (NCT05625386)
- 2025-11-17Phase 3 first posted: Ain Shams University, N Acetyl Cysteine + Vitamin D (Cholecalciferol ) (NCT07229456)
- 2025-09-24Results posted on the registry: Columbia University, Daily oral vitamin D3, 3,333 IU + Monthly oral vitamin D3, 100,000 IU (NCT04170348)
- 2025-09-22Results posted on the registry: Wihuri Research Institute, a drug against VDR (NCT04152291)
- 2025-09-17Results posted on the registry: Rodolfo Alejandro, Cholecalciferol + Omega 3 fatty acid (NCT03406897)
- 2025-09-12Results posted on the registry: Centre Hospitalier Departemental Vendee, a drug against VDR (NCT02044133)
- 2025-09-04Also stopped (terminated): Barichella Michela, a drug against VDR (NCT04306536)
- 2025-08-22Results posted on the registry: VA Office of Research and Development, a drug against VDR (NCT04485611)
- 2025-08-22Results posted on the registry: VA Office of Research and Development, a drug against VDR (NCT01229878)
- 2025-05-28Results posted on the registry: BPGbio, Compound 31543 Calcitriol 5 μg/mL + Compound 31543 Calcitriol 10 μg/mL (NCT01588522)
- 2025-03-30Results posted on the registry: OPKO Health, Inc., Calcifediol Oral Capsule + Placebo oral capsule (NCT03602261)
- 2025-03-21Results posted on the registry: LEO Pharma, LEO 90100 + Daivobet® ointment (NCT05919082)
- 2025-02-28Phase 3 first posted: M.D. Anderson Cancer Center, Fluorouracil 5-FU + Fluorouracil/Calcipotriene (NCT06851507)
- 2025-02-06Results posted on the registry: Ascelia Pharma AB, Mangoral (NCT04119843)
- 2024-12-10Results posted on the registry: HonorHealth Research Institute, Nivolumab + Albumin-bound paclitaxel (NCT02754726)
- 2024-11-27Phase 3 first posted: Sengkang General Hospital, Vitamin D (NCT06708741)
- 2024-10-21Results posted on the registry: University of Connecticut, blackcurrant (BC) extract (NCT04431960)
- 2024-08-26Phase 3 first posted: Professor Klaus Bønnelykke, a drug against VDR (NCT06570889)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision